Human Clinical Trials Of HIV/AIDS Vaccine Making Steady Progress

The first and only preventative HIV vaccine based on a genetically modified killed whole-virus has been making steady progress in Phase I Clinical Trials in the United States and the interim results are being analyzed in preparation for the next steps. Developed by Dr. Chil-Yong Kang and his team at Western University’s Schulich School of Medicine & Dentistry, with the support of Sumagen Canada, the vaccine (SAV001-H) holds tremendous promise for success in the final phases of clinical testing now that the first hurdle has been accomplished… (Source: Health News from Medical News Today)
MedWorm: Dentistry